NCT04519619View on ClinicalTrials.gov

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

RecruitingOBSERVATIONAL
Enrollment

480

Participants

Timeline

Start Date

November 27, 2020

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Neovascular Glaucoma
Interventions
DRUG

Aflibercept (Eylea, BAY86-5321)

Administration by intravitreal injection

Trial Locations (1)

Unknown

RECRUITING

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04519619 - Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG) | Biotech Hunter | Biotech Hunter